Press release
April 30, 2021
Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference
April 21, 2021
Immunicom Recognized as One of the Best Places to Work in the U.S.
March 26, 2021
Oncology Investors to Hear “Cancer Device Company of the Year” Immunicom Present at MedInvest Conference
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
January 25, 2021